Trial Profile
A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Nonacog beta pegol (Primary)
- Indications Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms paradigm 2
- Sponsors Novo Nordisk
- 01 Jan 2024 Results from HOPE-B, PROLONG-9FP, B-LONG and Paradigm 2, published in the Haemophilia
- 23 Sep 2019 Results of pooled analysis of three trials (PARADIGM 2, PARADIGM 4 and PARADIGM 5) assessing plasma PEG concentrations in children, adolescents and adults undergoing once-weekly intravenous prophylactic treatment with N9-GP for up to 6.5 years, published in the BioDrugs.
- 06 Jun 2017 According to a media release, the company expects to launch Refixia in the first Europe